Search company, investor...
BioLineRx company logo




Total Raised


Date of IPO


Market Cap


About BioLineRx

BioLineRx is a biopharmaceutical development company dedicated to identifying, in-licensing and developing therapeutic candidates for unmet medical needs or that have advantages over currently available therapies. BioLineRx's development pipeline consists of five clinical stage candidates as well as 11 candidates in various pre-clinical stages for indications including CNS, oncology, cardiovascular and autoimmune diseases. Two of BioLineRx's lead compounds have been out-licensed for continuation of development and commercialization.

Headquarters Location

19 Hartum Street PO Box 45158

Har Hahozvim, 91450,


Missing: BioLineRx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioLineRx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing BioLineRx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioLineRx is included in 2 Expert Collections, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

BioLineRx Patents

BioLineRx has filed 1 patent.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Monoclonal antibodies
  • Monoclonal antibodies for tumors
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Transcription factors, Cytokines, Experimental cancer drugs, Acute myeloid leukemia


Application Date


Grant Date



Related Topics

Clusters of differentiation, Transcription factors, Cytokines, Experimental cancer drugs, Acute myeloid leukemia



Latest BioLineRx News

BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates - BioLi

Nov 15, 2022

Benzinga By Pr Newswire - Announced FDA acceptance of APHEXDA (motixafortide) New Drug Application (NDA) in stem cell mobilization with Prescription Drug User Fee Act (PDUFA) target action date of September 9, 2023- - Introduced plan to commercialize APHEXDA independently in the U.S., if approved, and named Holly May, President, BioLineRx USA - - Completed $40M debt financing agreement and $15M equity offering to support aggressive commercial U.S. launch of APHEXDA - - Management to hold conference call today, November 15, at 10:00 am EST - AD AD TEL AVIV, Israel, Nov. 15, 2022 /PRNewswire/ -- BioLineRx Ltd. BLRX BLRX, a pre-commercial-stage biopharmaceutical company focused on oncology, today reported third quarter financial resultsand recent corporate and portfolio updates. The Company delivered outstanding performance during the third quarter and subsequent period. Last week's FDA acceptance of our new drug application for APHEXDA (motixafortide) substantially advances our twin goals of delivering an important new therapy for the mobilization of stem cells in preparation for autologous transplantation in patients with multiple myeloma, and in parallel, transitioning to a commercial stage company, said Philip Serlin, Chief Executive Officer of BioLineRx. Importantly, we took steps that allow us to rapidly commercialize APHEXDA, if approved, including securing financing, building out our U.S. operations, and progressing our launch strategy. We believe that APHEXDAhas the potential to become the standard-of-care mobilizing agent for multiple myeloma patients.

BioLineRx Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioLineRx Rank

BioLineRx Frequently Asked Questions (FAQ)

  • Where is BioLineRx's headquarters?

    BioLineRx's headquarters is located at 19 Hartum Street, Har Hahozvim.

  • What is BioLineRx's latest funding round?

    BioLineRx's latest funding round is IPO.

  • How much did BioLineRx raise?

    BioLineRx raised a total of $9M.

  • Who are the investors of BioLineRx?

    Investors of BioLineRx include Pitango Venture Capital, Giza Venture Capital and Teva Pharmaceuticals.

  • Who are BioLineRx's competitors?

    Competitors of BioLineRx include Bone Biologics, BioCogent, Rotation Medical, ZEDIRA, Cellular Engineering Technologies and 11 more.

Compare BioLineRx to Competitors

Raylab srl

Raylab is a communication design company with expertise in the biotechnology industry


BioCogent is a biotechnology company. It operates a portfolio of companies that manufacture and distribute generic drugs, equipment, and drugs for nuclear medicine. Additionally, its companies conduct research on new drugs, as well as a complex of vivarium laboratories that develop high technology drugs in the biotechnology sector.

Aurora Biomed Logo
Aurora Biomed

Aurora Biomed is a biotechnology company

Catapult Biomedical

Catapult is a San Diego-based incubator for biomedical start-ups.


BioRegenix is a biotechnology company committed to the development of tissue regeneration technology.

Cellular Engineering Technologies

Cellular Engineering Technologies is a biotechnology tissue engineering company.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.